Reduction of infection-related mortality after allogeneic PBSCT from HLA-identical siblings: Longitudinal analysis from 1994 to 2008 at a single institution

Bone Marrow Transplantation

Volumn 46, Issue 5, 2011, Pages 690-701

  Martino, R ^a,b   Kerguelen, A ^a   Valcarcel D ^a   Sureda, A ^a   Fachini, L ^a   Pinana J L ^a   Briones, J ^a   Delgado, J ^a   Brunet, S ^a   Sierra, J ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

allogeneic; infections; PBSCT

Indexed keywords

CYCLOSPORIN A; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; BACTERIAL INFECTION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FEMALE; GRAFT VERSUS HOST REACTION; HERPES SIMPLEX VIRUS 1; HLA MATCHING; HODGKIN DISEASE; HUMAN; INFECTION; INFECTION RATE; INFECTION RISK; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SIBLING; SYSTEMIC MYCOSIS; VARICELLA ZOSTER VIRUS; VIRUS PNEUMONIA;

ADULT; BACTEREMIA; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFECTION; LEUKEMIA; MULTIVARIATE ANALYSIS; MYCOSES; MYELODYSPLASTIC SYNDROMES; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; SIBLINGS; TRANSPLANTATION, HOMOLOGOUS; VIRUS DISEASES;

EID: 79955925059     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2010.177     Document Type: Article

References (28)

1. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 2009; 15: 1143-1238
2. Frassoni F, Labopin M, Powles R, Mary JY, Arcese W, Bacigalupo A et al. Effect of centre on outcome of bonemarrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 2000; 355: 1393-1398
3. Gratwohl A, Brand R, Frassoni F, Rocha V, Niederwieser D, Reusser P et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant 2005; 36: 757-769 (Pubitemid 41613298)
4. Przepiorka D, Smith TL, Folloder J, Khouri I, Ueno NT, Mehra R et al. Risk factors for acute graft-versus-host disease after allogeneic blood stem cell transplantation. Blood 1999; 94: 1465-1470 (Pubitemid 29380428)
5. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 2005; 11: 945-956 (Pubitemid 41754712)
6. Martino R, Caballero MD, Canals C, Simon JA, Solano C, Urbano-Ispizua A et al. Allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: results of a prospective multicentre study. Br J Haematol 2001; 115: 653-659 (Pubitemid 34015658)
7. Martino R, Valcarcel D, Brunet S, Sureda A, Sierra J. Comparable non-relapse mortality and survival after HLAidentical sibling blood stem cell transplantation with reduced or conventional-intensity preparative regimens for high-risk myelodysplasia or acute myeloid leukemia in first remission. Bone Marrow Transplant 2008; 41: 33-38
8. Martino R, Rovira M, Carreras E, Solano C, Jorge S, De La RJ et al. Severe infections after allogeneic peripheral blood stem cell transplantation: a matched-pair comparison of unmanipulated and CD34+ cell-selected transplantation. Haematologica 2001; 86: 1075-1086 (Pubitemid 33031874)
9. Urbano-Ispizua A, Rozman C, Pimentel P, Solano C, de la RJ, Brunet S et al. The number of donor CD3(+) cells is the most important factor for graft failure after allogeneic transplantation of CD34(+) selected cells from peripheral blood from HLA-identical siblings. Blood 2001; 97: 383-387 (Pubitemid 32060321)
10. Martino R, Bretagne S, Einsele H, Maertens J, Ullmann AJ, Parody R et al. Early detection of Toxoplasma infection by molecular monitoring of Toxoplasma gondii in peripheral blood samples after allogeneic stem cell transplantation. Clin Infect Dis 2005; 40: 67-78 (Pubitemid 40053461)
11. Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG et al. Hematopoietic cell transplantation (HCT)- specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood 2005; 106: 2912-2919 (Pubitemid 41510773)
12. Martino R, Caballero MD, Canals C, San MJ, Sierra J, Rovira M et al. Reduced-intensity conditioning reduces the risk of severe infections after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant 2001; 28: 341-347 (Pubitemid 32834351)
13. Bacigalupo A, Sormani MP, Lamparelli T, Gualandi F, Occhini D, Bregante S et al. Reducing transplant-related mortality after allogeneic hematopoietic stem cell transplantation. Haematologica 2004; 89: 1238-1247
14. Cantoni N, Weisser M, Buser A, Arber C, Stern M, Heim D et al. Infection prevention strategies in a stem cell transplant unit: impact of change of care in isolation practice and routine use of high dose intravenous immunoglobulins on infectious complications and transplant related mortality. Eur J Haematol 2009; 83: 130-138
15. Gratwohl A, Stern M, Brand R, Apperley J, Baldomero H, de WT et al. Risk score for outcome after allogeneic hematopoietic stem cell transplantation: a retrospective analysis. Cancer 2009; 115: 4715-4726
16. Gahrton G, Svensson H, Cavo M, Apperly J, Bacigalupo A, Bjorkstrand B et al. Progress in allogenic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983-93 and 1994- 8 at European Group for Blood and Marrow Transplantation centres. Br J Haematol 2001; 113: 209-216 (Pubitemid 32423325)
17. Blijlevens NM, Donnelly JP, DePauw BE. Inflammatory response to mucosal barrier injury after myeloablative therapy in allogeneic stem cell transplant recipients. Bone Marrow Transplant 2005; 36: 703-707 (Pubitemid 41518713)
18. van V, Blijlevens NM, Feuth T, Donnelly JP. Febrile mucositis in haematopoietic SCT recipients. Bone Marrow Transplant 2009; 43: 55-60
19. Martino R, Maertens J, Bretagne S, Rovira M, Deconinck E, Ullmann AJ et al. Toxoplasmosis after hematopoietic stem cell transplantation. Clin Infect Dis 2000; 31: 1188-1195
20. Boeckh M, Kim HW, Flowers ME, Meyers JD, Bowden RA. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation- a randomized double-blind placebo-controlled study. Blood 2006; 107: 1800-1805 (Pubitemid 43289356)
21. Parody R, Martino R, Rovira M, Vazquez L, Vazquez MJ, de la CR et al. Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation. Biol Blood Marrow Transplant 2006; 12: 734-748 (Pubitemid 43899409)
22. Safdar A, Rodriguez GH, Mihu CN, Mora-Ramos L, Mulanovich V, Chemaly RF et al. Infections in nonmyeloablative hematopoietic stem cell transplantation patients with lymphoid malignancies: spectrum of infections, predictors of outcome and proposed guidelines for fungal infection prevention. Bone Marrow Transplant 2010; 45: 339-347
23. Martino R, Subira M, Rovira M, Solano C, Vazquez L, Sanz GF et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002; 116: 475-482 (Pubitemid 34155525)
24. Perez-Simon JA, ez-Campelo M, Martino R, Sureda A, Caballero D, Canizo C et al. Impact of CD34+ cell dose on the outcome of patients undergoing reduced-intensity-conditioning allogeneic peripheral blood stem cell transplantation. Blood 2003; 102: 1108-1113 (Pubitemid 36917813)
25. Urbano-Ispizua A. High stem cell dose in haemopoietic transplantation: is it always beneficial? Leukemia 2003; 17: 1467-1469 (Pubitemid 36986948)
26. Mohty M, Bilger K, Jourdan E, Kuentz M, Michallet M, Bourhis JH et al. Higher doses of CD34+ peripheral blood stem cells are associated with increased mortality from chronic graft-versus-host disease after allogeneic HLA-identical sibling transplantation. Leukemia 2003; 17: 869-875 (Pubitemid 36626313)
27. Zaucha JM, Gooley T, Bensinger WI, Heimfeld S, Chauncey TR, Zaucha R et al. CD34 cell dose in granulocyte colonystimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98: 3221-3227
28. Mehta J, Frankfurt O, Altman J, Evens A, Tallman M, Gordon L et al. Optimizing the CD34 + cell dose for reducedintensity allogeneic hematopoietic stem cell transplantation. Leuk Lymphoma 2009; 50: 1434-1441